Advancing the health and well-being of animals and people


Principal Investigator: Kelly Hume

Contact Information: Email: krh73@cornell.edu; Phone: N/A
Sponsor: American Lung Association
Grant Number: N/A
Title: The Impact of Partial Impairment of the DNA Checkpoint Protein HUS1 on the Biology and Treatment of Lung Cancer
Annual Direct Cost: $40,000
Project Period: 07/01/2011 - 06/30/2012

DESCRIPTION (provided by applicant):  Lung cancer is the leading cause of cancer deaths in the United States, with over 150,000 people dying of the disease annually and an additional 200,000 new cases diagnosed each year. The reported relative 5-year survival rate is 50% for patients with localized disease and an abysmal 3% for patients with distant metastasis. This research determines if checkpoint impairment can halt lung cancer progression and if checkpoint impairment can sensitize lung cancer to cisplatin chemotherapy. In mammalian cells, the Atm and Atr checkpoint pathways function to protect DNA from damage. Although the tumor suppressor functions of the ATM pathway are well known, the functions of the Atr pathway in cancer are poorly understood. It is unclear whether pathway impairment will deprive cancer cells of a critical stress response, such that the cancer cells cannot survive and cell death occurs. To address this uncertainty, this work combines checkpoint impairment with oncogene activation in a mouse model of lunch cancer.